相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1952
进行中（未招募）
1
50.0%
已完成
1
50.0%
暂无批准数据
- myTomorrows announced its first large-scale partnership in Spain with Clínica Universidad de Navarra to implement AI-assisted patient-trial matching technology integrated within the hospital's electronic health record system. - The AI system leverages large language models to analyze clinical variables and cross-check patient information against eligibility criteria across CUN's portfolio of more than 200 active clinical trials. - The collaboration introduces a phased deployment model that enables clinicians to access structured lists of potentially eligible trials directly within patient records during routine clinical workflows. - A CUN-branded referral platform will allow external physicians to AI-pre-screen patients and submit referrals with real-time visibility into trial availability and cohort status.
- Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025 to advance its Phase 2 OCTOPOD-IV clinical trial of THEO-260 in platinum-resistant ovarian cancer. - THEO-260 is a novel oncolytic immunotherapy designed to kill both cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich solid tumors. - The competitive funding award validates the company's innovative approach to addressing significant unmet medical needs in patients with advanced ovarian cancer, whose life expectancy is typically one year or less. - The grant will support up to 20 patients in the Phase 2a expansion study and involves major international clinical centers including institutions in Spain, Canada, and the UK.
- Theriva Biologics will present expanded data from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer at ESMO 2025, building on previous clinical results from 142 patients treated across multiple cancer types. - The company will showcase preclinical data for VCN-12, a next-generation oncolytic adenovirus armed with additional transgenes designed to improve tumor cell lysis and enhance stroma degradation compared to VCN-01. - New preclinical research demonstrates the feasibility of intracranial VCN-01 administration for brain tumor treatment, with investigators concluding the findings provide strong rationale for further development in this indication. - SYN-004 interim safety and pharmacokinetic data from an ongoing Phase 1b/2a trial in allogeneic hematopoietic cell transplant recipients will be presented at IDWeek 2025.
- The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya. - Over 20,000 participants in Kwale County, Kenya received monthly ivermectin doses for three consecutive months, showing significant malaria reduction with only mild, transient side effects. - The World Health Organization's vector control advisory group has reviewed the findings and recommended further studies, marking a potential breakthrough in malaria control strategies. - Beyond malaria prevention, ivermectin treatment provided additional benefits including reduced prevalence of scabies, head lice, and bed bugs in treated communities.
